MedPath

Prospective Evaluation of Diagnostic Accuracy of Endoscopic Ultrasound-guided Fine Needle Aspiration and Biopsy (EUS-FNAB) in the Absence of Rapid Onsite Evaluation

Completed
Conditions
Pancreatic Cancer
Interventions
Procedure: EUS-FNA
Registration Number
NCT02079285
Lead Sponsor
Kangbuk Samsung Hospital
Brief Summary

\<Background/aims\> Rapid onsite evaluation (ROSE) of endoscopic ultrasound-guided fine needle aspiration and biopsy (EUS-FNAB) specimens by attending cytopathologists has been demonstrated to improve diagnostic yields of EUS-FNAB. The practice of ROSE, however, varies across EUS programs in Unites States, Europe and other areas of world. The investigators have a plan to perform prospective evaluation of the yield of EUS-FNAB in the absence of ROSE, in which the adequacy of specimens will be assessed by a single endosonographer.

\<Methods\> All EUS-FNAB procedures will be performed by an experienced endosonographer and the adequacy of specimens obtained during EUS-FNAB will be also assessed by a same endosonographer. A specimen will be considered adequate if there is an adequate number of representative cells from the lesion. Samples considered to be adequate will be then interpreted as malignancy, highly atypical suggestive of malignancy, atypical favor reactive change, or negative for malignancy. Performance characteristics of EUS-FNAB including sensitivity, specificity, and accuracy will be determined by comparing EUS-FNAB results with the final diagnoses of the lesions, based upon the surgical pathology or clinical follow-up of more than 6 months with repeat imagings.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
75
Inclusion Criteria
  • Any patients who will undergo EUS-FNA for the diagnostic evaluation of pancreas lesion
Exclusion Criteria
  • Patients who refuse to undergo EUS-FNA

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
EUS-FNAEUS-FNAAny patients who will undergo EUS-FNA for pancreas lesion during the study period
Primary Outcome Measures
NameTimeMethod
Sensitivity, specificity and accuracy of EUS-FNA without ROSE7 days

Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of EUS-FNA without ROSE

Secondary Outcome Measures
NameTimeMethod
Adequacy of obtained cytologic specimens7 days

Trial Locations

Locations (1)

Sungkyunkwan University Kangbuk Samsung Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath